azacitidine msn azacitidine 100 mg powder for injection vial
juno pharmaceuticals pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.
vaxigrip
medici medical ltd, israel - a/michigan/45/2015 (h1n1)pdm09-like virus; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) - suspension for injection - b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) 15 mcg/dose; a/michigan/45/2015 (h1n1)pdm09-like virus 15 mcg/dose; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 15 mcg/dose; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg/dose - influenza, inactivated, whole virus - influenza, inactivated, whole virus - for the prevention of influenza.
influvac
abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - suspension for injection - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.
agrippal s1
neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.
enzira suspension for injection, pre-filled syringeinfluenza vaccine (split virion, inactivated)
seqirus gmbh - b/colorado/06/2017-like strain (b/victoria/2/87 lineage)(b/maryland/15/2016,nymc bx-69a); a/michigan/45/2015 (h1n1) pdm09 - like strain (a/singapore/gp1908/2015, ivr-180a); a/singapore/imfimh-16-0019/2016 (h3n2)-like strain (a/singapore/infimh-16-0019/2016,nib-104); b/colorado/06/2017 - like strain (b/maryland/15/2016,wild type) - suspension for injection - 0 percent - influenza vaccines; influenza, inactivated, split virus or surface antigen
fluad, suspension for injection in pre-filled syringeinfluenza vaccine, surface antigen, inactivated, adjuvanted with mf59c.1(20
seqirus s.r.l. - a/michigan/45/2015 (h1n1) pdm09 - like strain (a/singapore/gp1908/2015, ivr-180a); a/singapore/imfimh-16-0019/2016 (h3n2)-like strain (a/singapore/infimh-16-0019/2016,nib-104); b/colorado/06/2017-like strain (b/victoria/2/87 lineage)(b/maryland/15/2016,nymc bx-69a) - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen - influenza vaccine - active immunisation against influenza in the elderly (65 years of age and over. refer to spc for detailed information.
fluquadri suspension for injection (im)
sanofi pasteur, inc.; distributor: zuellig pharma corporation - quadrivalent seasonal influenza vaccine (split) virion, inactivated) 2024 southern hemisphere strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains the following influenza strains*: a/sydney/5/2021 (h1n1) pdm09-like virus (a/sydney/5/2021, san-013) 15 μg of ha** a/darwin/9/2021 (h3n2)-like virus (a/darwin/9/2021, ivr-228) 15 μg of ha** b/austria/1359417/2021 (b/victoria lineage)-like virus (b/michigan/01/2021, wild type) 15 μg of ha** b/phuket/3073/2013 (b/yamagata lineage)-like virus (b/phuket/3073/2013, wild type) 15 μg of ha** *propagated in fertilized hen's eggs from healthy chicken flocks **haemagglutinin
fluarix tetra suspension for injection (im)
glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2024 strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin
equip wnv (previously duvaxyn wnv)
zoetis belgium sa - inactivated west nile virus, strain vm-2 - immunologicals for equidae - horses - for the active immunisation of horses of six months of age or older against west-nile-virus disease by reducing the number of viraemic horses.
hydrocortisone tablet
carilion materials management - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis pem